This Outlook Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Avi Kapoor 3 hours ago
MarketsTrading IdeasPre-Market OutlookNewsAnalyst RatingsInitiation
Analysts initiated coverage: Anthropic (ANT) Buy/$150 and Outperform/$135; LASE Buy/$2; OTLK Overweight/$4; KINS Overweight/$24.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Needham analyst Scott Berg initiated coverage on Anthropic (NASDAQ:ANT) with a Buy rating and announced a price target of $150. See how other analysts view this stock.
- HC Wainwright & Co. analyst Daniil Gataulin initiated coverage on LASE Corp. (NASDAQ:LASE) with a Buy rating and announced a price target of $2. Lase shares closed at $0.3923 on Wednesday. See how other analysts view this stock.
- Piper Sandler analyst David Amsellem initiated coverage on Outlook Therapeutics, Inc. (NASDAQ:OTLK) with an Overweight rating and announced a price target of $4. Innoviva closed at $0.4079 on Wednesday. See how other analysts view this stock.
- Wolfe Research analyst Alex Zukin initiated coverage on Anthropic (NASDAQ:ANT) with an Outperform rating and announced a price target of $135. See how other analysts view this stock.
- Piper Sandler analyst Paul Newsome initiated coverage on Kingstone Companies, Inc. (NASDAQ:KINS) with an Overweight rating and announced a price target of $24. Kingstone closed at $22.31 on Wednesday. See how other analysts view this stock.
Considering buying OTLK stock? Here’s what analysts think:

Photo via Shutterstock
